Exome Asset Management
Exome Asset Management reported 55 stocks worth $153M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are GH (7.9%), TGTX (6.8%) and ABVX (5.9%). Compared with Q2 2026, the fund opened new positions in CMPS, CLDX and MRK, added to TGTX, ABVX and PRAX, trimmed TXG, UTHR and UNH and sold out of AGIO, CBIO and AZN.
Latest filing: what Exome Asset Management did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() GH Guardant Health Inc | $12M | 7.9% | 68K | No change | 8 of 8 | |
| 2 | ![]() TGTX TG Therapeutics Inc | $10.5M | 6.8% | 188K | +23K (+14%) | 2 of 8 | |
| 3 | ![]() ABVX Abivax SA | $9M | 5.9% | 91K | +44K (+94%) | 2 of 8 | |
| 4 | ![]() PRAX Praxis Precision Medicines I | $8.6M | 5.7% | 30K | +2,476 (+9%) | 6 of 8 | |
| 5 | ![]() COGT Cogent Biosciences Inc | $6.7M | 4.4% | 211K | No change | 7 of 8 | |
| 6 | ![]() LLY Eli Lilly & Co | $6.4M | 4.2% | 5,492 | No change | 8 of 8 | |
| 7 | ![]() NTRA Natera Inc | $5.7M | 3.7% | 14K | No change | 8 of 8 | |
| 8 | ![]() VERA Vera Therapeutics Inc | $5.2M | 3.4% | 160K | +62K (+64%) | 6 of 8 | |
| 9 | ![]() VKTX Viking Therapeutics Inc | $4.8M | 3.1% | 147K | +100K (+208%) | 2 of 8 | |
| 10 | ![]() IONS Ionis Pharmaceuticals Inc | $4.8M | 3.1% | 107K | +19K (+21%) | 8 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
![]() AGIO Agios Pharmaceuticals Inc | $2.6M | 71K |
![]() CBIO Crescent Biopharma Inc. | $2.3M | 128K |
![]() AZN Astrazeneca PLC Ord | $2.3M | 12K |
![]() INSM Insmed Inc | $1.5M | 14K |
![]() RLAY Relay Therapeutics Inc | $889K | 48K |
🔒 Free account: see all 6.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Exome Asset Management 13F FAQ
What does Exome Asset Management own?
Exome Asset Management reported 55 stocks worth $153M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are GH (7.9%), TGTX (6.8%) and ABVX (5.9%). The table above lists every position in the filing (the top 10 without an account).
What did Exome Asset Management buy and sell in Q3 2026?
Compared with Q2 2026: 9 new positions, 17 added to, 8 trimmed and 6 sold out. New positions include CMPS, CLDX and MRK. It sold all of AGIO, CBIO and AZN.
When will Exome Asset Management file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Exome Asset Management's portfolio worth?
The Q3 2026 filing reports $153M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.


























